Kymera Therapeutics Inc (NASDAQ:KYMR) — Market Cap & Net Worth
Market Cap & Net Worth: Kymera Therapeutics Inc (KYMR)
Kymera Therapeutics Inc (NASDAQ:KYMR) has a market capitalization of $8.51 Billion ($8.51 Billion) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #2490 globally and #913 in its home market, demonstrating a -6.32% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kymera Therapeutics Inc's stock price $103.40 by its total outstanding shares 82257588 (82.26 Million). See Kymera Therapeutics Inc capital spending ratio to understand how much of operating cash flow is reinvested back into capital assets.
Kymera Therapeutics Inc Market Cap History: 2020 to 2026
Kymera Therapeutics Inc's market capitalization history from 2020 to 2026. Data shows growth from $5.10 Billion to $8.51 Billion (21.02% CAGR).
Index Memberships
Kymera Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.35% | #52 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.02% | #287 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.72 Trillion | 0.49% | #35 of 263 |
Weight: Kymera Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Kymera Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kymera Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
163.28x
Kymera Therapeutics Inc's market cap is 163.28 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $5.10 Billion | $34.03 Million | -$45.59 Million | 149.85x | N/A |
| 2021 | $5.22 Billion | $72.83 Million | -$100.22 Million | 71.71x | N/A |
| 2022 | $2.05 Billion | $46.83 Million | -$154.81 Million | 43.85x | N/A |
| 2023 | $2.09 Billion | $78.59 Million | -$146.96 Million | 26.65x | N/A |
| 2024 | $3.31 Billion | $47.07 Million | -$223.86 Million | 70.30x | N/A |
| 2025 | $6.40 Billion | $39.20 Million | -$311.40 Million | 163.28x | N/A |
Competitor Companies of KYMR by Market Capitalization
Companies near Kymera Therapeutics Inc in the global market cap rankings as of August 3, 2026.
Key companies related to Kymera Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Kymera Therapeutics Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Kymera Therapeutics Inc's market cap moved from $5.10 Billion to $ 8.51 Billion, with a yearly change of 21.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $8.51 Billion | +32.89% |
| 2025 | $6.40 Billion | +93.41% |
| 2024 | $3.31 Billion | +58.01% |
| 2023 | $2.09 Billion | +2.00% |
| 2022 | $2.05 Billion | -60.69% |
| 2021 | $5.22 Billion | +2.40% |
| 2020 | $5.10 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 2nd, 2026 the market cap of Kymera Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.51 Billion USD |
| MoneyControl | $8.51 Billion USD |
| MarketWatch | $8.51 Billion USD |
| marketcap.company | $8.51 Billion USD |
| Reuters | $8.51 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kymera Therapeutics Inc
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CR… Read more